Table 3.
Kaplan‐Meier survival analysis for non‐CKD and CKD group
| Non‐CKD | CKD | ||||
|---|---|---|---|---|---|
| Median (months) | 95% CI | Median (months) | 95% CI | P | |
| Age | 0.58 | ||||
| <75 | 10.28 | 8.11–12.46 | 9.80 | 7.34–12.24 | 0.36 |
| >75 | 6.34 | 4.65–8.03 | 5.39 | 3.94–6.84 | 0.92 |
| Gender | 0.52 | ||||
| Female | 10.87 | 7.39–14.36 | 7.26 | 4.14–10.38 | 0.34 |
| Male | 6.90 | 5.98–7.82 | 7.10 | 5.83–8.37 | 0.86 |
| Smoking history | 0.44 | ||||
| No | 9.30 | 7.01–11.59 | 7.79 | 6.11–9.46 | 0.60 |
| Yes | 7.46 | 5.86–9.06 | 7.10 | 5.42–8.77 | 0.57 |
| Comorbidity score | 0.76 | ||||
| <9 | 8.67 | 6.49–10.86 | 9.99 | 7.74–12.24 | 0.59 |
| >9 | 7.52 | 5.99–9.06 | 6.11 | 4.76–7.46 | 0.36 |
| Stage | 0.25 | ||||
| Stage I–IIIA | 35.84 | 28.71–42.97 | 24.80 | 16.77–32.84 | 0.14 |
| Stage IIIB–IV | 6.67 | 5.52–7.82 | 5.98 | 4.78–7.17 | 0.52 |
| Histology | 0.39 | ||||
| NSCLC | 9.62 | 7.94–11.31 | 7.79 | 6.39–9.19 | 0.20 |
| SCLC | 4.24 | 3.33–5.15 | 4.66 | 0.52–8.80 | 0.35 |
| Treatment | 0.71 | ||||
| Supportive treatment | 3.05 | 2.29–3.82 | 2.40 | 1.56–3.24 | 0.42 |
| Medical treatment | 8.25 | 6.60–9.89 | 8.70 | 7.11–10.30 | 0.75 |
| Surgical treatment | 52.14 | 30.66–73.61 | 41.72 | 19.55–63.90 | 0.75 |
CI, confidence interval; CKD, chronic kidney disease; NSCLC, non‐small cell lung cancer; SCLC, small cell lung cancer.